Anti-infective
Arexvy has become the first RSV vaccine to show it can provide protection over three years – but that might mean lower market uptake than originally expected.
One of Enanta’s two antivirals in development for RSV showed efficacy in a healthy patient challenge trial. But analysts say field studies of infected patients are more telling.
Deal Snapshot: Merck likes the look of Evaxion's artificial intelligence-based technology platform to develop immunotherapies and signed a biobucks deal that will help ease the Copenhagen-headquartered biotech's financial situation.
The company said the CENTERSTONE study marked the first time a global Phase III trial showed reduced transmission of influenza.
The company stands a strong chance of winning approval for lenacapavir as a twice-yearly injectable drug for preventing HIV infection, though market challenges remain.
Its vaccine candidate will now proceed to Phase III, but might be hard pressed to compete against Moderna’s flu plus COVID-19 combination shot.
Failure of GSK’s targeted immunotherapy leaves field open for Moderna and BioNTech candidates.
The cash-strapped Danish biotech has got some positive news flow on its vaccines for gonorrhea and melanoma and believes that Phase II data on the latter in particular will attract attention at the major oncology conference kicking off in Barcelona this week.
The company’s VAX-31 against 31 pneumococcal serotypes outperformed Pfizer’s market-leading Prevnar 20 and could provide the broadest coverage of any vaccine in its class.
While they wait for the results from their Phase III study, the partners have posted more impressive mid-stage data on what could be the first approved vaccine for a couple of decades to protect against infection from ticks.
The specialist pharma company hopes demand for mpox vaccines will help establish its vaccine platform, but cash and investor confidence remain in short supply.
Serum Institute is working on an mpox vaccine while other Indian firms are weighing options after the WHO sounded an alert and a new case was reported in neighboring Pakistan. Scrip looks at factors that could favor development and/or manufacture of an mpox vaccine at Indian majors.
The company will ramp up manufacturing of its Jynneos vaccine to meet demand in worst-affected African countries and stockpiling richer nations.
The commercial implications of the miss are hard to call, but separate trials could offer hope.
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.
Second quarter revenues are up but RSV jab woes drag on the company’s stock.
In this week's podcast edition of Five Must-Know Things: Narasimhan plays the long game; Merck & Co’s RSV contender; Mounjaro’s China approval; the mid-cap rising stars; and AI could add billions in drug revenues.
Beyfortus was a minimal contributor in Sanofi’s second quarter, which beat consensus and prompted an earnings guidance boost, but the RSV antibody’s sales should surge in Q3 and Q4.
A Phase IV study showed that ViiV’s Dovato was non-inferior to Gilead’s Biktarvy on efficacy and produced less weight gain.
Phase IIb/III trial testing Merck’s prophylactic monoclonal antibody clesrovimab met the primary safety and efficacy endpoints to protect infants from RSV, but the market is competitive.